These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38524636)

  • 41. Phenotype, genotype and glycaemic variability in people with activating mutations in the ABCC8 gene: response to appropriate therapy.
    Reilly F; Sanchez-Lechuga B; Clinton S; Crowe G; Burke M; Ng N; Colclough K; Byrne MM
    Diabet Med; 2020 May; 37(5):876-884. PubMed ID: 31562829
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Four Cases of Maturity Onset Diabetes of the Young (MODY) Type 5 Associated with Mutations in the Hepatocyte Nuclear Factor 1 Beta (HNF1B) Gene Presenting in a 13-Year-Old Boy and in Adult Men Aged 33, 34, and 35 Years in Poland.
    Motyka R; Kołbuc M; Wierzchołowski W; Beck BB; Towpik IE; Zaniew M
    Am J Case Rep; 2021 Feb; 22():e928994. PubMed ID: 33526762
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A beneficial role of GLP-1 receptor agonist therapy in ABCC8-MODY (MODY 12).
    Nakhleh A; Goldenberg-Furmanov M; Goldstein R; Shohat M; Shehadeh N
    J Diabetes Complications; 2023 Sep; 37(9):108566. PubMed ID: 37536118
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
    Frias JP; Deenadayalan S; Erichsen L; Knop FK; Lingvay I; Macura S; Mathieu C; Pedersen SD; Davies M
    Lancet; 2023 Aug; 402(10403):720-730. PubMed ID: 37364590
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Maturity-onset diabetes of the young (MODY): an update.
    Anık A; Çatlı G; Abacı A; Böber E
    J Pediatr Endocrinol Metab; 2015 Mar; 28(3-4):251-63. PubMed ID: 25581748
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
    Weng J
    J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis.
    Andreadis P; Karagiannis T; Malandris K; Avgerinos I; Liakos A; Manolopoulos A; Bekiari E; Matthews DR; Tsapas A
    Diabetes Obes Metab; 2018 Sep; 20(9):2255-2263. PubMed ID: 29756388
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes.
    Hedrington MS; Tsiskarishvili A; Davis SN
    Expert Opin Biol Ther; 2018 Mar; 18(3):343-351. PubMed ID: 29431519
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Maturity Onset Diabetes of the Young due to Glucokinase, HNF1-A, HNF1-B, and HNF4-A Mutations in a Cohort of Turkish Children Diagnosed as Type 1 Diabetes Mellitus.
    Ozsu E; Cizmecioglu FM; Yesiltepe Mutlu G; Yuksel AB; Calıskan M; Yesilyurt A; Hatun S
    Horm Res Paediatr; 2018; 90(4):257-265. PubMed ID: 30481753
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genetic and Clinical Characterization of Patients with Maturity-Onset of Diabetes of the Young (MODY): Identification of Novel Variations.
    Ateş EA; Üstay Ö; Polat H; Apaydın T; Elbasan O; Yıldırım Ö; Güney Aİ
    Balkan Med J; 2021 Sep; 38(5):272-277. PubMed ID: 34462253
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
    Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B
    J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244
    [No Abstract]   [Full Text] [Related]  

  • 52. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
    Malkin SJP; Russel-Szymczyk M; Psota M; Hlavinkova L; Hunt B
    Adv Ther; 2019 Aug; 36(8):2034-2051. PubMed ID: 31168765
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Factors associated with glycemic variability in children with type 1 diabetes mellitus based on flash glucose monitoring system.
    Zhang L; Guo K; Xu Y; Bai J; Ma Y; Fu L; Liu J; Hu K; Li X; Jiang H; Yang L
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 47(4):462-468. PubMed ID: 35545341
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A case of MODY5-like manifestations without mutations or deletions in coding and minimal promoter regions of the HNF1B gene.
    Kuwabara-Ohmura Y; Iizuka K; Liu Y; Takao K; Nonomura K; Kato T; Mizuno M; Hosomichi K; Tajima A; Miyazaki T; Horikawa Y; Yabe D
    Endocr J; 2020 Sep; 67(9):981-988. PubMed ID: 32461507
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expanded clinical spectrum in hepatocyte nuclear factor 1b-maturity-onset diabetes of the young.
    Raile K; Klopocki E; Holder M; Wessel T; Galler A; Deiss D; Müller D; Riebel T; Horn D; Maringa M; Weber J; Ullmann R; Grüters A
    J Clin Endocrinol Metab; 2009 Jul; 94(7):2658-64. PubMed ID: 19417042
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial.
    Kellerer M; Kaltoft MS; Lawson J; Nielsen LL; Strojek K; Tabak Ö; Jacob S
    Diabetes Obes Metab; 2022 Sep; 24(9):1788-1799. PubMed ID: 35546450
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of Patient-Reported Satisfaction and Clinical Efficacy of Once-Weekly Semaglutide in Patients with Type 2 Diabetes: An Ambispective Study.
    Al Hayek AA; Al Dawish MA
    Adv Ther; 2022 Apr; 39(4):1582-1595. PubMed ID: 35119622
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparing once-weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis.
    Mishriky BM; Cummings DM; Powell JR; Sewell KA; Tanenberg RJ
    Diabetes Metab; 2019 Apr; 45(2):102-109. PubMed ID: 30243806
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of once-weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE Canada multicentre, prospective, observational study.
    Yale JF; Catarig AM; Grau K; Harris S; Klimek-Abercrombie A; Rabasa-Lhoret R; Reardon L; Woo V; Liutkus J
    Diabetes Obes Metab; 2021 Oct; 23(10):2269-2278. PubMed ID: 34142429
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
    Davies M; Pieber TR; Hartoft-Nielsen ML; Hansen OKH; Jabbour S; Rosenstock J
    JAMA; 2017 Oct; 318(15):1460-1470. PubMed ID: 29049653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.